查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1947511

肿瘤人工智慧市场：依组件、癌症类型和应用划分－全球预测至2036年

AI in Oncology Market by Component, Cancer Type, and Application - Global Forecast to 2036
出版日期: | 出版商: Meticulous Research | 英文 255 Pages | 商品交期: 5-7个工作天内

价格
简介目录

全球肿瘤人工智慧（AI）市场预计将从2026年的54亿美元成长到2036年的约495.3亿美元，预测期内（2026-2036年）复合年增长率（CAGR）为24.8%。

本报告对全球五大主要地区的肿瘤人工智慧市场进行了详细分析，重点关注当前市场趋势、市场规模、最新发展以及至2036年的预测。透过广泛的二级和一级研究以及对市场现状的深入分析，我们对关键产业驱动因素、限制因素、机会和挑战进行了影响分析。

推动肿瘤人工智慧市场成长的关键因素包括全球对精准医疗日益增长的兴趣以及智慧诊断框架在不同临床生态系统中的快速扩展。 此外，深度学习演算法的快速普及、对高性能医学成像的需求不断增长、基因组分析能力的提高以及与数位医疗的日益融合，预计将为在肿瘤学人工智慧市场运营的公司创造巨大的成长机会。

市场区隔

目录

第一章：引言

第二章：摘要整理

第三章：市场概览

  • 市场动态
    • 驱动因素
    • 限制因素
    • 机遇
    • 挑战
  • 市场趋势
    • 生成式人工智慧和多模态资料整合的普及
    • 边缘人工智慧和即时临床决策支援的创新
    • 人工智慧驱动药物发现的进展
  • 监理框架与标准
  • 波特五力分析
  • PESTEL分析
  • 价值链分析

第四章：全球肿瘤人工智慧市场（依组件划分）

  • 软体解决方案
    • 人工智慧平台
    • 云端解决方案
  • 硬体
    • 处理器（GPU、TPU）
    • 储存设备
    • 网路系统
  • 服务
    • 专业服务
    • 託管服务

第五章：全球肿瘤人工智慧市场（依癌症类型划分）

  • 乳癌
  • 肺癌
  • 前列腺癌
  • 大肠直肠癌
  • 脑瘤
  • 其他

第六章：全球肿瘤人工智慧市场（依应用划分）

  • 诊断
    • 医学影像
    • 体外诊断
  • 治疗计划
    • 放射治疗
    • 化学治疗
    • 免疫治疗
  • 药物发现与开发
  • 研究与临床试验
  • 其他

第七章：全球肿瘤人工智慧市场（依最终用户划分）

  • 医院和诊断中心
  • 製药和生技公司
  • 学术和研究机构
  • 其他

第八章：全球肿瘤人工智慧市场（依地区划分）

  • 北美
    • 美国美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 智利
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 南非
    • 埃及
    • 以色列
    • 中东其他地区非洲

第九章 竞争格局

  • 市占率分析
  • 竞争格局概览
    • 行业领导者
    • 市场差异化因素
    • 先锋企业
    • 新兴企业
  • 近期策略发展

第十章：公司简介

  • Siemens Healthineers AG
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips N.V.
  • NVIDIA Corporation
  • Intel Corporation
  • IBM Corporation
  • Google LLC
  • Microsoft Corporation
  • ConcertAI
  • PathAI
  • Azra AI
  • iCAD, Inc.

第11章 附录

简介目录
Product Code: MRHC - 1041756

AI in Oncology Market by Component (Software Solutions, Hardware, Services), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Others), and Application (Diagnostics, Treatment Planning, Drug Discovery & Development, Others) - Global Forecast to 2036

According to the research report titled, 'AI in Oncology Market by Component (Software Solutions, Hardware, Services), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Others), and Application (Diagnostics, Treatment Planning, Drug Discovery & Development, Others) - Global Forecast to 2036,' the global AI in oncology market is expected to reach approximately USD 49.53 billion by 2036 from USD 5.40 billion in 2026, at a CAGR of 24.8% during the forecast period (2026-2036).

The report provides an in-depth analysis of the global AI in oncology market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.

The major factors driving the growth of the AI in oncology market include the intensifying global focus on precision medicine and the rapid expansion of intelligent diagnostic frameworks across diverse clinical ecosystems. Additionally, the rapid expansion of deep learning algorithms, increasing need for high-performance medical imaging, genomic analysis capabilities, and digital health integration are expected to create significant growth opportunities for players operating in the AI in oncology market.

Market Segmentation

The AI in oncology market is segmented by component (software solutions, hardware, services), cancer type (breast cancer, lung cancer, prostate cancer, others), application (diagnostics, treatment planning, drug discovery & development, others), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Component

By component, the hardware segment holds the largest market share in 2026, primarily attributed to its essential role in supporting high-performance computing and data storage in hospital environments. These systems provide the computational infrastructure necessary for processing complex medical imaging datasets and enabling real-time diagnostic analysis. However, the software solutions segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of AI algorithms for clinical decision support, image analysis automation, and personalized treatment planning. The ability to deliver integrated solutions with proven clinical efficacy makes advanced software platforms highly attractive for healthcare institutions.

Based on Cancer Type

By cancer type, the breast cancer segment holds the largest market share in 2026, primarily due to its efficacy in handling high-volume screening data and providing scalable, predictive results for early intervention. The widespread adoption of mammography screening programs and the availability of large training datasets have accelerated AI algorithm development in this segment. The lung cancer segment is expected to witness significant growth during the forecast period, driven by the need for early detection capabilities, advanced imaging analysis, and treatment optimization. Prostate cancer and other cancer types represent emerging segments with growing adoption of AI-driven diagnostic and therapeutic approaches.

Based on Application

By application, the diagnostics segment holds the largest share of the overall market in 2026, due to its critical role in early cancer detection and clinical decision support. AI-powered diagnostic systems provide enhanced accuracy, reduced false positives, and improved patient outcomes through advanced image analysis and pattern recognition. The treatment planning segment is expected to grow at a significant CAGR during the forecast period, driven by the need for personalized treatment protocols and improved therapeutic outcomes. Drug discovery and development applications represent emerging segments with substantial growth potential as pharmaceutical companies increasingly leverage AI for accelerated drug candidate identification and clinical trial optimization.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global AI in oncology market with the largest market share, primarily attributed to massive investments in AI research and development and the presence of leading technology innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by aggressive digital transformation initiatives and rapid adoption of AI-driven clinical services in China, India, and Japan. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing healthcare digitalization and increasing adoption of AI-powered oncology solutions.

Key Players

The key players operating in the global AI in oncology market are IBM Corporation, Microsoft Corporation, Google LLC, NVIDIA Corporation, Siemens Healthineers, Philips Healthcare, GE Healthcare, Varian (Siemens), Elekta AB, Tempus AI, Paige, Recursion Pharmaceuticals, Exscientia, PathAI, Ayasdi, and various other regional and emerging technology providers, among others.

Key Questions Answered in the Report-

  • What is the current revenue generated by the AI in oncology market globally?
  • At what rate is the global AI in oncology market demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the global AI in oncology market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of component, cancer type, and application are expected to create major traction for the service providers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global AI in oncology market?
  • Who are the major players in the global AI in oncology market? What are their specific product offerings in this market?
  • What are the recent strategic developments in the global AI in oncology market? What are the impacts of these strategic developments on the market?

Scope of the Report:

AI in Oncology Market Assessment -- by Component

  • Software Solutions
  • Hardware
  • Services

AI in Oncology Market Assessment -- by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Others

AI in Oncology Market Assessment -- by Application

  • Diagnostics
  • Treatment Planning
  • Drug Discovery & Development
  • Others

AI in Oncology Market Assessment -- by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Scope
  • 1.3. Research Methodology
  • 1.4. Assumptions & Limitations

2. Executive Summary

3. Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
    • 3.2.4. Challenges
  • 3.3. Market Trends
    • 3.3.1. Proliferation of Generative AI and Multimodal Data Integration
    • 3.3.2. Innovation in Edge AI and Real-Time Clinical Decision Support
    • 3.3.3. Advancements in AI-Driven Drug Discovery
  • 3.4. Regulatory Framework and Standards
  • 3.5. Porter's Five Forces Analysis
  • 3.6. PESTEL Analysis
  • 3.7. Value Chain Analysis

4. Global AI in Oncology Market, by Component

  • 4.1. Introduction
  • 4.2. Software Solutions
    • 4.2.1. AI Platforms
    • 4.2.2. Cloud-based Solutions
  • 4.3. Hardware
    • 4.3.1. Processors (GPUs, TPUs)
    • 4.3.2. Storage Devices
    • 4.3.3. Networking Systems
  • 4.4. Services
    • 4.4.1. Professional Services
    • 4.4.2. Managed Services

5. Global AI in Oncology Market, by Cancer Type

  • 5.1. Introduction
  • 5.2. Breast Cancer
  • 5.3. Lung Cancer
  • 5.4. Prostate Cancer
  • 5.5. Colorectal Cancer
  • 5.6. Brain Tumor
  • 5.7. Others

6. Global AI in Oncology Market, by Application

  • 6.1. Introduction
  • 6.2. Diagnostics
    • 6.2.1. Medical Imaging
    • 6.2.2. In-vitro Diagnostics
  • 6.3. Treatment Planning
    • 6.3.1. Radiation Therapy
    • 6.3.2. Chemotherapy
    • 6.3.3. Immunotherapy
  • 6.4. Drug Discovery & Development
  • 6.5. Research & Clinical Trials
  • 6.6. Others

7. Global AI in Oncology Market, by End User

  • 7.1. Introduction
  • 7.2. Hospitals & Diagnostic Centers
  • 7.3. Pharmaceutical & Biotechnology Companies
  • 7.4. Academic & Research Institutes
  • 7.5. Others

8. Global AI in Oncology Market, by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. UK
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. South Korea
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Argentina
    • 8.5.4. Chile
    • 8.5.5. Colombia
    • 8.5.6. Rest of Latin America
  • 8.6. Middle East & Africa
    • 8.6.1. Saudi Arabia
    • 8.6.2. UAE
    • 8.6.3. South Africa
    • 8.6.4. Egypt
    • 8.6.5. Israel
    • 8.6.6. Rest of Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Market Share Analysis
  • 9.3. Competitive Dashboard
    • 9.3.1. Industry Leader
    • 9.3.2. Market Differentiators
    • 9.3.3. Vanguards
    • 9.3.4. Emerging Companies
  • 9.4. Recent Strategic Developments

10. Company Profiles

  • 10.1. Siemens Healthineers AG
  • 10.2. GE HealthCare Technologies Inc.
  • 10.3. Koninklijke Philips N.V.
  • 10.4. NVIDIA Corporation
  • 10.5. Intel Corporation
  • 10.6. IBM Corporation
  • 10.7. Google LLC
  • 10.8. Microsoft Corporation
  • 10.9. ConcertAI
  • 10.10. PathAI
  • 10.11. Azra AI
  • 10.12. iCAD, Inc.

11. Appendix